Publication Cover
Canadian Journal of Pain
Revue canadienne de la douleur
Volume 7, 2023 - Issue 1
1,553
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Views on and experiences with medicinal cannabis among Canadian veterans who live with pain: A qualitative study

, MScORCID Icon, , BScORCID Icon, , PhDORCID Icon, , BSc, Gr.Dip.ORCID Icon, , PhDORCID Icon, , Pharm.DORCID Icon & ORCID Icon show all
Article: 2232838 | Received 08 Apr 2023, Accepted 30 Jun 2023, Published online: 08 Sep 2023

ABSTRACT

Background

During fiscal year 2021–2022, Veterans Affairs Canada (VAC) reimbursed 18,388 veterans for medicinal cannabis at a cost of $153 million. Yet, it is not known whether the reimbursement program is producing a net benefit for veterans.

Aims

This study investigated the views and experiences Canadian that veterans who live with pain have about medicinal cannabis use, including its use for the management of chronic pain, poor sleep, and emotional distress.

Methods

Twelve Canadian veterans who live with pain—eight men, four women; split across four focus groups—were recruited to participate in a semistructured discussion around their experiences with medicinal cannabis use.

Results

Using inductive thematic analysis, seven broad categories were identified: (1) cannabis use behaviors, (2) reasons for cannabis use, (3) outcomes from cannabis use, (4) facilitators of cannabis use, (5) barriers to cannabis use, (6) stigma around cannabis use, and (7) questions and concerns about cannabis use.

Conclusions

Most veterans initiated cannabis use to manage the symptoms of preexisting medical and/or mental health conditions. Despite some negative side effects, most veterans reported improvements in their overall quality of life, sleep, relationships, mood, and pain. Concern remains around the discrepancy between veterans’ qualitative reports of beneficial outcomes from medicinal cannabis use and equivocal findings around the benefit-to-harm ratio in the wider literature. Currently, the VAC reimbursement program remains challenged by unclear indication for which veterans, with what condition(s), at what dose, and in what form medical cannabis is most beneficial.

RÉSUMÉ

Contexte: Au cours de l’exercice 2021–2022, Anciens Combattants Canada (ACC) a remboursé 18 388 anciens combattants pour le cannabis médicinal, pour un coût de 153 millions de dollars. Pourtant, on ne sait pas si le programme de remboursement donne lieu à un bénéfice net pour les anciens combattants.

Objectifs: Cette étude porte sur les points de vue et les expériences des anciens combattants canadiens qui vivent avec la douleur sur la consommation de cannabis médicinal, y compris son utilisation pour la gestion de la douleur chronique, les problèmes de sommeil et la détresse émotionnelle.

Méthodes: Douze anciens combattants canadiens qui vivent avec la douleur - huit hommes et quatre femmes répartis en quatre groupes de discussion - ont été recrutés pour participer à une discussion semi-structurée autour de leurs expériences avec la consommation de cannabis médicinal.

Résultats: Une analyse thématique inductive a permis d’établir sept grandes catégories : (1) les comportements de consommation de cannabis, (2) les raisons de la consommation de cannabis, (3) résultats de la consommation de cannabis, (4) les facteurs qui facilitent la consommation de cannabis, (5) les obstacles à la consommation de cannabis, (6) la stigmatisation autour de la consommation de cannabis et (7) les questions et préoccupations concernant la consommation de cannabis.

Conclusions: La plupart des anciens combattants ont commencé à consommer du cannabis pour gérer les symptômes de maladies préexistantes et/ou des problèmes de santé mentale. Malgré certains effets secondaires négatifs, la plupart des anciens combattants ont signalé une amélioration de leur qualité de vie globale, de leur sommeil, de leurs relations, de leur humeur et de leur douleur. La préoccupation demeure autour de l’écart entre les rapports qualitatifs des anciens combattants décrivant les résultats bénéfiques de la consommation de cannabis médicinal et les résultats équivoques autour du rapport bénéfice/effet néfaste dans la littérature plus large. Actuellement, le programme de remboursement d’ACC reste contesté en raison d’indications peu claires concernant pour quels vétérans, atteints de quelles affections, à quelle dose et sous quelle forme le cannabis médical est le plus bénéfique.

Introduction

Veterans experience greater incidence of medical conditions than the general population. Forty-one percent of Regular Force Canadian veterans report living with chronic pain or discomfort, which is about twice the rate in the Canadian general population.Citation1 Canadian veterans with chronic pain are 11 times more likely to experience disabilities limiting their daily activity when compared to those without chronic pain.Citation2 The presence of chronic pain is associated with a higher prevalence of comorbidities compared to those without chronic pain.Citation3 For example, 79% of Canadian veterans with chronic pain report having a diagnosed mental health condition, and 83% report past-year suicidal ideation.Citation2,Citation4 Veterans also frequently report sleep-related difficulties associated with pain, such as insomnia, nightmares, and poor sleep quality.Citation5,Citation6 A systematic review of longitudinal studies found that a decline in sleep quality and quantity was associated with a two- to threefold increase in the risk of developing a pain condition and a decline in self-reported physical health status.Citation7 A systematic scoping review arrived at a similar conclusion, reporting that treatment-induced sleep improvements enhanced chronic pain outcomes.Citation8 Consistent with the comorbidity evident in the literature, Canadian veterans have indicated that optimizing chronic pain management as well as identifying and treating mental illness in veterans living with chronic pain are research priorities for their population.Citation9

Medicinal Cannabis in Canada

The use of cannabis for medical purposes among veterans has a long history in Canada. Formal reimbursement of medical cannabis by the Department of Veterans Affairs Canada (VAC) began in 2007. From 2008 to 2014, access to medical cannabis was limited by the Marihuana Medical Access Regulations, in which individuals required endorsement by a specialist physician to receive cannabis for medical use for select indications, including cancer, AIDS/HIV, multiple sclerosis, spinal cord injury or disease, epilepsy, or severe arthritis.Citation10 The Marihuana for Medical Purposes Regulations replaced the Marihuana Medical Access Regulations in April 2014, allowing nonspecialist physicians to prescribe for patients and removing restrictions based on indication.Citation10 Further revisions to legislation occurred in 2016 to allow authorized individuals to grow and purchase medical cannabis.

Medicinal cannabis regulatory changes occurring between 2014 and 2016 resulted in an increased number of veterans receiving medicinal cannabis authorization and reimbursement through VAC. Only 37 veterans were approved by VAC for medicinal cannabis authorizations in fiscal year 2011–2012 at a cost of $103,424.Citation11 By fiscal year 2016–2017, the program had expanded, reimbursing 4474 veterans at a cost of $63,703,151.Citation11 Due to the unforeseen increase in cannabis approvals among veterans, policy changes at VAC took place in 2016 to limit most recipients to 3 g of cannabis per day at a reimbursement rate of $8.50/g.Citation12 With this policy change, costs decreased to $50,967,423 in fiscal year 2017–2018, despite an increase in the number of veterans reimbursed for cannabis of 2824 over the year before. The production, distribution, sale, and consumption of cannabis for recreational use became legal with the passing of the Cannabis Act by the Government of Canada in October 2018, leading to greater awareness and social acceptance of cannabis use.Citation13 As of fiscal year 2021–2022, the number of veterans reimbursed has expanded to 18,388, with the total expenditure on cannabis exceeding $153 million.Citation11 Despite the annual expenditure on cannabis, it is not known whether the VAC reimbursement program is producing an appreciable net benefit in the lives of the veterans involved, leading to the suggestion that reimbursement and oversight guidelines should possibly be revisited.Citation14

Veterans’ Perceptions of Medicinal Cannabis

Most research on the medicinal use of cannabis has been conducted on civilians and assessed the efficacy of synthetic derivatives of cannabis such as nabilone or dronabinol.Citation15–17 The limited research that has been conducted on veteran populations was mostly conducted within the United States.Citation14,Citation18–21 In a qualitative cross-sectional case study on perceptions of cannabis use among 12 U.S. combat veterans, CrouletCitation19 reported that all but one preferred cannabis over pharmaceutical medications for treating anxiety and sleep disturbances. In a qualitative study on cannabis risk perception in a sample of 31 U.S. veterans, Wilkinson et al.Citation18 reported that most viewed cannabis as safe and not addictive and that this view was informed by individual experience with cannabis use. In an exploratory qualitative study of perceived risks and benefits of cannabis use with 23 early adult veterans and active-duty military members in the United States (aged 18–29; 10 veterans), Clary et al.Citation20 reported that most perceived cannabis as an attractive alternative to opioid and benzodiazepine medications and an effective treatment for physical ailments and mental health issues. The authors also noted that veterans perceived cannabis as carrying limited risks. Further studies have reported that veterans view cannabis as an effective treatment for symptoms associated with posttraumatic stress disorder (PTSD),Citation22 chronic pain,Citation23 sleep disturbances,Citation24 and emotional dysregulation.Citation25 Though there is currently a lack of scientific consensus on the therapeutic benefit of cannabis for veterans, there is also little knowledge of Canadian veterans’ subjective experience of using cannabis medicinally.

Aims

Little is known on the use of medicinal cannabis for the treatment of chronic pain, poor sleep, and symptoms of emotional distress among Canadian veterans living with pain. In particular, it is important to determine whether the use of medicinal cannabis has a positive, negative, or equivocal effect on the seven domains of veteran well-being as defined by the VAC, which include health, purpose, finances, social integration, life skills, housing and physical environment, and culture and social environment.Citation26

The primary objective of this qualitative study was to develop a better understanding of the views and experiences that Canadian veterans who live with pain have about medicinal cannabis use, including its use for the management of chronic pain, poor sleep, and emotional distress.

Methods

The goal of this qualitative study was to conduct four focus groups. Based on work by Guest et al.Citation27 data saturation of 90% can usually be achieved with three to six focus groups, and most new information in a qualitative data set is generated early in the process, with a relatively sharp decline in new information occurring after just a small number of data collection/analysis events.Citation28

Participants

Participants were recruited through the Chronic Pain Center of Excellence for Canadian veterans. The Chronic Pain Center of Excellence has established a list of veterans who have consented to participate in research. A fan-out recruitment message detailing the goals of the focus group was sent to all 1135 veterans on the list at the time of recruitment. There is a significant gender imbalance in the Canadian Armed Forces (CAF), where one in six CAF members are women.Citation29 We purposefully recruited women to reduce this gender imbalance and ensure that one-third of participants were women. Participation was voluntary, and interested veterans signed up and completed informed consent forms online. Participants were offered a $25 gift card for their time.

To be included in the study, a participant had to be a Canadian veteran—at least 18 years of age—with self-identified chronic pain who has or is currently using licensed medicinal cannabis authorized by the VAC. Individuals were excluded if they were nonveterans (i.e., active armed forces service members or civilians), were unable to read and write in English, were currently pregnant or breastfeeding, or were planning to become pregnant during the observation period.

Procedure

This study was approved by the Hamilton Integrated Research Ethics Board. Focus groups were conducted using the Zoom virtual conferencing platform. Participants were sent guidelines to follow to ensure privacy and confidentiality during the focus group, such as using a private space and ensuring that others could not overhear the conversation or view participants.

Focus groups were recorded, transcribed verbatim using the NVivoCitation30 transcription service, and de-identified. The video recordings were combined with their associated transcripts to identify the contributions of each participant who were assigned a unique participant identification number. Transcripts were not returned to participants for comment or correction.

Focus Groups

Focus groups were conducted by members of the Healthcare Human Factors team, University Health Network, Toronto, and observed by G.T., V.P., and J.A.. The Healthcare Human Factors team was recruited owing to their expertise in facilitating focus groups to identify stakeholder priorities. Focus groups consisted of two to four veterans, lasted on average 90 min, and were conducted between February 16, 2022, and March 23, 2022. Men and women were in separate focus groups because of the high prevalence of sexual assault endured by women in the CAF at the hands of male service members.Citation31 The women participating appreciated the opportunity to share their experiences in the exclusive company of other women. The research team developed a qualitative focus group guide that queried experiences with medicinal cannabis use (see Appendix). After introductions, participants were asked to reflect on a series of opening questions and then share their thoughts with the group one by one. Afterward, more specific questions were asked to uncover the research questions that veterans were most interested in getting answers to. The facilitators then reflected on the themes that had arisen and probed deeper to fill in gaps and flesh out thematic areas where necessary. For example, barriers and facilitators of medicinal cannabis use emerged as general themes and were probed more deeply.

Data Synthesis

Transcripts were independently reviewed by D.S. and N.K.-V. to determine initial codes using open coding.Citation32 A codebook with definitions of codes was derived through an iterative process of discussion and consensus. Discrepancies that could not be resolved through consensus were brought forward to the remaining authors for discussion and resolution. In accordance with grounded theory, inductive thematic analysis was used to identify common themes, and axial coding was used with each coder independently completing one of the two remaining focus group discussions.Citation32–34 Individual quotations were linked to multiple codes as appropriate. The constant comparative method was used throughout this process, with codes and themes being continuously revisited to ensure that they fit the data.Citation33,Citation34 To be included, a subtheme had to have a combined value of ≥5, based on the number of focus groups in which the subtheme was raised plus the number of participants who endorsed that subtheme. The codebook was reviewed by all members of the team.

Reflexivity

This review was undertaken by a multidisciplinary team with diverse viewpoints and experiences with the medicinal use of cannabis among veterans, including three practicing clinical psychologists (all male) with expertise in addictions and chronic pain management; one practicing pharmacist (male) with expertise in medicinal cannabis and chronic pain management; one research coordinator (female) with a background in medical science and experience with project management; one research assistant (female) pursuing a degree in applied psychological science with a background in qualitative and quantitative research, program evaluation, mental health and addictions, cannabis use, and chronic pain; and one trainee (male) pursuing a degree in clinical psychology with a background in experimental psychology, experience as a former research assistant with the Cannabis Health Evaluation Research Partnership (CHERP–MUN School of Pharmacy), and lived experience as a Canadian Armed Forces Veteran with 14 years of service in the reserve and regular forces combined. Members of our team engage in regular clinical practice and have clinical experience working with people—including veterans—who use medicinal cannabis to manage symptoms associated with chronic pain, poor sleep, and PTSD. Members of our team are also involved in federal mentorship programs for chronic pain, substance use, mental health, and addictions.

It is important that we acknowledge the lens through which our study team sought, coded, and identified emergent themes to enhance trustworthiness of findings. We have wide familiarity with chronic pain management, opioid use, medicinal cannabis, and veteran mental health in the fields of psychology, pharmacy, and medicine. Moreover, we have a keen interest in ensuring that the symptom management needs of veterans are being met in a safe, efficient, and effective manner. We strive to remain as objective as possible, focusing on what was explicitly discussed by the focus group participants, rather than trying to infer meaning during the coding process. We had a civilian (N.K.-V.) and a veteran (D.S.) conduct the initial coding and inductive thematic analysis independently to control for potential bias stemming from civilian and veteran perspectives.

Findings

The final sample consisted of 12 Canadian veterans split across four focus groups. None of the veterans who consented to participate dropped out.

Demographic characteristics for the veterans who participated in this study are displayed in . Compared to the broader veteran population in Canada, our sample included a higher percentage of women (33% compared to 13%), veterans aged 20 to 39 (33% compared to 10%), and veterans aged 40 to 59 (50% compared to 29%) and a lower percentage of veterans aged 60+ (17% compared to 46%).Citation35

Table 1. Veterans’ demographic characteristics.

We identified 42 subthemes subsumed within 17 distinct themes and split across seven broader categories, including cannabis use behaviors, reasons for cannabis use, outcomes from cannabis use, facilitators of cannabis use, barriers to cannabis use, stigma around cannabis use, and questions and concerns about cannabis use. The emergent themes based on thematic analysis are displayed in .

Table 2. Emergent themes.

A detailed subtheme breakdown is displayed in . Participants did not provide feedback on the findings.

Table 3. Summary of findings.

Cannabis Use Behaviors

Timing of cannabis initiation was the first theme that emerged, with initiation occurring either prior to joining the military (n = 4, 33%) or after release from military service (n = 3, 25%):

I used a lot of cannabis when I was younger before I joined, completely stopped while I served, and I restarted maybe a month after release. (Male veteran)

Most veterans reported having used cannabis for the past 3 to 7 years with a mode of 4 years. The most common form of medicinal cannabis used was ingestible, with some veterans taking cannabis capsules or pills (n = 5, 42%) and others taking edibles (n = 3, 25%).

Reasons for Cannabis Use

The most cited reason for using cannabis was to manage the symptoms of preexisting conditions, with comorbid conditions (e.g., pain, depression, anxiety) being the norm (n = 7, 58%):

My whole body is pretty much just broken from head to toe, same as Veteran 3, you know, crawling under aircraft lift and everything, the whole bit. So, I’ve got bad knees, bad feet, bad back, neck, migraines, depression, and that was what got me into cannabis. (Male veteran)

Regarding specific medical conditions, veterans endorsed chronic pain (n = 8, 67%), musculoskeletal injury (n = 6, 50%), sleep disturbances (n = 5, 42%), PTSD (n = 4, 33%), depression (n = 4, 33%), and anxiety (n = 3, 25%). One of the primary motivators for veterans switching from other pharmacological treatments for their preexisting medical conditions to medicinal cannabis was avoidance of undesirable side effects. Many veterans expressed that negative side effects from taking prescription opioids (e.g., stomach pain, endocrine dysregulation, flat affect, suicidality, addiction) motivated their switch to cannabis (n = 7, 58%):

Just like Veteran 11, I cannot do those drugs for pain, it just killed my stomach. So, between having pain in my stomach and pain in my joints and everything else I’m just going to choose the pain in my joints because it’s … at least I know why I have it. (Female veteran)

Several veterans (n = 3, 25%) also reported undesirable effects from taking gabapentin (e.g., suicidality, mental fog, exacerbation of symptoms of PTSD) as a reason for switching to cannabis.

Outcomes from Cannabis Use

Veterans reported that being able to replace multiple pharmacological treatments with cannabis had resulted in beneficial outcomes (n = 10, 83%):

I feel good on [cannabis]. I have stopped over the counter meds, have stopped other medications, so I’m just strictly right now on cannabis. I think that’s good. (Male veteran)

Specifically, veterans reported that being able to replace multiple pharmacological treatments with cannabis had improved their overall quality of life (n = 7, 58%):

When I’m coming along good and I’m walking, I’m out with my dog and doing my yard work and having … the best day of my life. I’m really happy that the CBD is working its magic. (Female veteran)

Veterans also reported that switching to cannabis improved their sleep (n = 6, 50%), relationships with friends and family (n = 5, 42%), and mood (n = 4, 33%) and allowed them to manage their symptoms more effectively (n = 3, 25%). Veterans did report potential negative side effects from cannabis use, such as an unpleasant taste or smell of cannabis oils (n = 4, 33%), and feeling intoxicated, anxious, and/or paranoid after using too much cannabis (n = 4, 33%):

I get paranoid if I take too much, so I will get paranoid really easy, so that’s always finding that little perfect sweet spot. But yeah, it’s usually decent. (Male veteran)

Some veterans reported general side effects of cannabis use irrespective of the dose consumed, such as dry mouth, throat or sinus irritation, increased appetite, and weight gain (n = 4, 33%).

Facilitators of Cannabis Use

Veterans reported that receiving financial support for medicinal cannabis from the VAC was easy (n = 5, 42%):

Weirdly enough, getting coverage was super easy. It’s three months of struggle to get my driveway clean, but $1000 bucks of cannabis a month was not even hard. I find it weird, but who am I to judge? (Male veteran)

More than half of veterans interviewed reported receiving support for obtaining medicinal cannabis from private medical cannabis clinics (n = 7, 58%). These private medical cannabis clinics specifically serve the needs of veterans by filling prescriptions, facilitating reimbursement, providing suggestions for cannabis products to try, as well as scheduling and coordinating health care services. They also provide information, social activities, and peer support for veterans:

I went through [a private cannabis clinic] here in [a Canadian city] just because they helped with all the paperwork getting the doctor, you know, getting the prescription with Veterans Affairs and the whole bit, right. So, I didn’t really have to do anything other than show up for doctors’ appointments and still with [a private cannabis clinic] if I have questions or anything you know that there’s a point of contact. I contact her and she’s really quick to respond, give me the answers I need, that sort of thing and she’s been really helpful. (Male veteran)

Some veterans reported experiencing support from members of the public health care system for their cannabis use. For example, some veterans reported feeling supported in their decision to use medicinal cannabis from psychiatrists and psychologists (n = 4, 33%), as well as from nurses and family physicians (n = 2, 17%). Veterans reported that their primary source of information about cannabis is from peers, family, and/or friends (n = 4, 33%):

I still have my friends that I see they’re all using cannabis now too so we’re all in the same boat. We’re all getting older, or pain is starting to develop more. We’re all ex-military and sort of been used hard and put away wet and we didn’t get the proper brush down we should have been getting. … We play on each other’s past. … I know the edibles really don’t […] work too well for me but the capsules in the oil do and I’ve got friends where it’s the opposite way … so we just use each other. (Male veteran)

Barriers to Cannabis Use

A majority of veterans reported that difficulty finding a family physician or accessing health care services was a barrier to medicinal cannabis use (n = 8, 67%). Some veterans reported difficulty obtaining a stable supply of medicinal cannabis (n = 4, 33%). Others noted disruptions in their access to medicinal cannabis due to difficulties in switching providers (n = 4, 33%):

You can switch providers but there is a delay to it and it messes with your order sequence or order timings I guess, because when you switch from one provider to another provider your order date then changes and potentially the product you’re ordering can change too so if one provider doesn’t have what you had before you’re trying to figure out what’s going to work for you again and then you could go through 2 to 3 months of trial and experimentation to figure out what’s going to work for you on a new provider. (Male veteran)

Restrictions placed on one’s ability to travel between provinces or internationally was a common complaint regarding cannabis medication (n = 6, 50%):

Travel is a big negative thing too because … we want to sell our place here in Canada and start traveling … and that’s … kind of got me worried because I don’t want to go back on opioids. (Male veteran)

Concern about cannabis-related driving restrictions was also noted (n = 3, 25%).

A lack of support and knowledge within the civilian health care system around medicinal cannabis use was another theme to emerge. Several veterans perceived that civilian health care providers had insufficient scientific medical knowledge around cannabis (n = 5, 42%):

Went back to my family doctor, said, “What about this cannabis stuff, would that help me?” And she kind of looked at me like a deer in the headlights, like she didn’t know about cannabis and medical uses. She had heard about it, but she didn’t know the details. (Male veteran)

Related to this, many veterans expressed insufficient guidance around how to use cannabis (e.g., quantity and timing of dosage) from medical professionals and cannabis suppliers (n = 4, 33%). Veterans reported an overreliance on prescribing narcotics for pain management by health care professionals. Many shared experiences where they felt that they were prescribed more opioids to manage their pain than was necessary and that this was done without giving due consideration to alternatives such as cannabis (n = 5, 42%):

When I fractured my spine … they immediately went to oxy’s [i.e., Oxycodone]. They said, “Here’s a 30 count of oxy, take it. It’s going to make you feel better.” … I looked at it, I’m like, “Should I actually take this or not?” Fifteen days go by. I go back to another appointment they’re like, “Oh so did you take the medication?” I lied to them, said, “Yes, I did.” They gave me another 30 count of boxes. It’s just like, like what the hell are they doing? You can get addicted after taking 30 of those pills, and they gave me 60 in 30 days. I didn’t take them, but like this is how preposterous it is. (Male veteran)

Several veterans also reported confusion due to unclear product information, poor packaging, and difficulty opening the bottles in which their medicinal cannabis was packaged (n = 3, 25%).

Stigma around Cannabis Use

One in four veterans interviewed reported stigmatizing experiences within the public health care system around disclosing cannabis use or requesting a medicinal cannabis prescription (n = 3, 25%):

[During] the intake for my nose surgery when I … went through the list of drugs, cannabis of course wasn’t a drug anymore, it’s legal, but then when we got to that point where we had to discuss my cannabis use, it went from I was a normal person to the look on her face was, she was … suddenly looking at an addict and I could feel the temperature in the room change. It was bizarre. (Male veteran)

A majority of veterans reported experiences of stigma around cannabis use within society that largely stemmed from a prelegalization “War on Drugs”–era mindset (n = 7, 58%):

I’ll use the example of … my mother-in-law [who] is against cannabis: it’s a drug. [She has a] little older mentality; it’s been illegal [her] whole life. They still see it as a drug. … At one point I walked out of the base hospital with a patch of fentanyl [on] my shoulder, hydromorphone by mouth, and even Vicodin as a breakthrough. So, I had three hardcore narcotics that can easily kill you, especially the three together, but she saw it [as] better than using CBD. (Male veteran)

Self-stigma (i.e., the internalization of systemic and public stigma around cannabis use) had a divergent impact on veterans’ decision to use cannabis. Some veterans reported that self-stigma delayed their adoption of medicinal cannabis (n = 5, 42%):

[Stigma] impacted my start with [cannabis] I wish I’d started you know a couple of years before I actually did, but that was all delayed because of stigma. (Male veteran)

However, one in three veterans interviewed reported that systemic and public stigma did not impact their decision to use cannabis (n = 4, 33%):

I could care less what other people think about it because I’m not taking a long list of drugs anymore and it helps me substantially. (Female veteran)

Questions and Concerns about Cannabis Use

Veterans reported a lack of clarity surrounding proper cannabis dosage and noted difficulty determining the correct dose to treat specific symptoms without resorting to a trial-and-error approach to find the correct dosage (n = 6, 50%):

I think I had some ups and downs with it to get the dosage right, but now that it is [right] it seems to be working fairly well. Not as good as I wanted it to, but I think it’s just a matter of tweaking other things too. (Male veteran)

Several veterans wanted more information about how to use cannabis to effectively manage specific symptoms (n = 3, 25%). For example, what specific strains, dosages, and schedules of cannabis consumption are advisable to manage symptoms of PTSD versus chronic pain? Veterans also had questions and concerns about the potential long-term effects of using cannabis (n = 6, 50%):

I think the biggest thing that I struggle with is what’s the daily marijuana use going to do to my mind in 30 years? … I haven’t really been able to see anything or any type of studies or reports actually saying what prolonged marijuana use does to someone’s brain. I don’t know if it’s all just a wives’ tale. I don’t know if they said that to deter people from using marijuana [in the past], right? I think that for me … that’s my biggest question. … Everything else I’m pretty good with, but I think it’s just the long-term impacts of using it [that] I’m interested in. (Male veteran)

There was also some interest in knowing more about the specific effects of the different terpenes—naturally occurring chemical compounds—within cannabis (n = 3. 25%).

Themes Requiring Additional Exploration

There were 21 subthemes subsumed within 11 distinct themes that did not meet the threshold to be included in the summary of findings table. Almost all subthemes in this table were endorsed by only one or two veterans. Two subthemes were endorsed by three veterans but within a single focus group. Veterans were interested in learning more about how to transition from other medications to cannabis (n = 3, 25%), as well as what ratios of THC to CBD are optimal for the management of different symptoms (n = 3, 25%). details the themes requiring additional exploration.

Table 4. Themes requiring additional exploration.

Interpretation

This is one of few studies to qualitatively examine Canadian veterans’ views on and experiences with medicinal cannabis and the only study to date that has included views of male and female veterans.

Reasons for Cannabis Use

Veterans experienced at least one medical condition for which medicinal cannabis was prescribed; however, it was clear that comorbidity was the norm, with most veterans experiencing concurrent medical conditions (e.g., chronic pain, musculoskeletal injury, insomnia, PTSD, depression, anxiety). For this reason, most veterans were taking multiple medications to manage their complex symptoms, which were often accompanied by negative side effects, particularly in the case of opioids and, to a lesser degree, gabapentin. In many cases, it was the quantity and severity of negative side effects from other medications that motivated the switch to medical cannabis. This aligns with qualitative work by Clary et al.Citation20 on cannabis use among young U.S. military members and veterans who reported using cannabis as an alternative to opioid and benzodiazepine medications for the treatment of physical ailments. It also aligns with work by CrouletCitation19 on perceptions of cannabis use among U.S. veterans who reported that cannabis has fewer side effects compared to pharmaceuticals and did not hinder any aspects of their life. In a study by Krediet et al.Citation36 on experiences with medicinal cannabis in the treatment of PTSD in veterans from the Netherlands, all participants reported having fewer side effects using cannabis than with conventional medications. Baumbusch and Sloan YipCitation37 conducted a qualitative study among civilians to investigate new cannabis use among older adults (65 years or older) and observed that the main reasons for cannabis were pain management, as a sleep aide, and as an alternative to over-the-counter medications to avoid negative side effects associated with those medications.Citation37

Outcomes from Cannabis Use

Veterans reported beneficial outcomes from their switch to medical cannabis, including improvements in sleep quality, interpersonal relationships, mood, and quality of life. Several veterans interviewed replaced medications that targeted a single symptom with cannabis, which they believed had diffuse effects that improved multiple symptoms. This is not to say that medical cannabis is a side effect–free panacea. Some veterans reported experiencing dry mouth, throat or sinus irritation, increased appetite, and weight gain from cannabis use. These findings accord with qualitative studies on perceptions of the risks and benefits of medicinal cannabis use among U.S.Citation18–20,Citation35 and DutchCitation35 veterans that observed that most veterans perceived the benefits of cannabis use to outweigh the harms. This seems to conflict with a qualitative synthesis on cannabis use among military veterans by Turna and MacKillop,Citation14 who cited evidence of associations between cannabis use and negative health outcomes, increased substance use, psychiatric disorders, and increased self-harm.

Self-reports of benefit from medicinal cannabis use in the absence of clear evidence raises the possibility of a placebo response. In fact, cannabis has been found to activate psychoneuroimmunological mechanisms shown to mediate placebo analgesia, which may explain why it is often used by individuals who experience chronic pain.Citation37,Citation38 CasarettCitation39 argued that placebo-controlled trials of medicinal cannabis have been flawed by inadequate blinding, making them susceptible to the placebo response, potentially leading to an overestimate of the effectiveness of medical cannabis. Findings on the role of the placebo response with respect to cannabis use also tie into the perception of risk associated with its use. A qualitative study on the formation of risk perception around cannabis use in a sample of veterans receiving treatment for a substance use disorder identified that the most salient factor informing risk perception was an individual’s personal experience with cannabis.Citation18 An important implication is that individuals who cannot identify any losses or negative experiences associated with their own cannabis use are less likely to consider potential harms. Considering this, it is worth exploring whether there is a selection bias in qualitative studies on cannabis use whereby individuals who have had positive experiences with cannabis are more likely to volunteer for such studies. Conversely, many studies may be conducted in treatment centers with a strong bias against the use of cannabis for medicinal purposes.Citation40,Citation41

Facilitators of Cannabis Use

Several veterans commented on how efficient receiving coverage through the VAC for medical cannabis was, which is contrary to low support from medical doctors in Canada.Citation42,Citation43 This ease of receiving coverage was appreciated by many veterans and facilitated medical cannabis use, which is associated with the growth and cost of the VAC cannabis reimbursement program and the growing number of private medical cannabis clinics targeted toward veterans that have opened for business in recent years.Citation44 This growth is perhaps at odds with the gaps in knowledge about medicinal use, including the lack of a clear indication of what dose and form of medicinal cannabis will be of benefit for veterans with different conditionsCitation19—questions that veterans would like answers to as well.

Many veterans reported positive experiences with private medical cannabis clinics because they help in navigating the reimbursement system, completing VAC paperwork, obtaining a prescription for medical cannabis, scheduling and coordinating health care services, and answering questions about cannabis.Citation45 Some of these clinics also put on social activities for veterans, offering a sense of community as well as opportunities for peer support. A shortage of family physicians in many regions of the country is another reason why many veterans have gravitated toward these private clinics, because that may be the only way to obtain a prescription.Citation46 These clinics are filling a gap in care and direction that was missing for veterans; however, consideration of the private, for-profit nature of these clinics is warranted. Some provincial medical colleges have expressed concern about physicians charging patients for consultation as well as the use of one-off telemedicine sessions in the absence of a thorough case review and assessment of need.Citation44,Citation47 Some of the veterans in our study reported being prescribed the maximum daily reimbursable dose of cannabis by physicians at these clinics in the absence of expressed need. This echoes a concern expressed by Kahan et al.Citation47 that a lack of regulatory oversight of cannabis clinic protocols could result in patients being prescribed an excessive dose. Of course, the paucity of research on medicinal cannabis dosing for different conditions contributes to this problem, making it difficult for prescribers to know how much is indicated for a given patient with a given condition.Citation48,Citation49 Nevertheless, there have been efforts to establish safe practice guidelines for the use of medicinal cannabis.Citation50–54

Barriers to Cannabis Use

Several veterans reported past experiences of feeling intoxicated, anxious, or paranoid while using cannabis. The likelihood and severity of these side effects would be expected to vary with dose, ratio of THC to CBD, and method of consumption (e.g., smoked versus ingested). In many cases, veterans identified a dosage, strain, and method of consumption that minimized or avoided these side effects through their own process of trial and error. A lack of guidance around dosing of medicinal cannabis necessitating a trial-and-error approach by the user has been cited as a concern in numerous studiesCitation35,Citation48,Citation49,Citation55 and was reported by Canadian veterans in our study. Reliance on unvetted sources of information and experimentation with dosing is a potentially dangerous approach that could result in overdosing and negative experiences with cannabis or underdosing and therefore failure to gain therapeutic benefit. Resolving confusion around dosage may help veterans avoid some of these potential pitfalls, though numerous challenges remain in establishing safe and accurate dosing information in the regulated cannabis market.Citation48,Citation49

Some of the barriers to medicinal cannabis use reported by veterans seem to relate to growing pains within the cannabis industry generally. For example, the difficulty in obtaining a stable supply has affected both the medicinal and recreational markets since legalization.Citation56,Citation57 These disruptions in supply have left many veterans having to switch providers, which can be troublesome because it is delayed by paperwork and approvals, resulting in a lapse of coverage. There may be scope for the VAC to streamline the process of switching providers to help ameliorate this challenge for veterans.

Restrictions to driving and travel were frequently reported barriers to medicinal cannabis use reported by veterans in this study. This aligns with a qualitative study of veterans in the Netherlands.Citation35 In a survey of adult cannabis users in Canada (N = 1093), Wickens et al.Citation58 observed that most believe that frequent recreational and medical cannabis users can drive safely after exposure to cannabis. This is despite at least three systematic reviews and meta-analyses that suggest that the acute use of cannabis increases collision risk.Citation59–61 In a narrative review of the impact of cannabis on road safety, Brands et al.Citation62,Citation64 concluded that “‘cannabis is cannabis’ and it produces impairments in driving, regardless of whether it is used for recreational or medical purposes.”(pCitation5) This discrepancy between user perception and the literature is concerning given that a higher proportion of medical cannabis users engage in driving under the influence of cannabis, relative to recreational-only users.Citation58 However, as pointed out by Turna and MacKillop,Citation14 medical cannabis users may be more likely than recreational users to opt for products with lower THC levels, which could reduce the collision risk associated with use. Some of the veterans in this study reported that their daily medicinal cannabis use precluded them from being able to drive without fear of prosecution and therefore limited their ability to travel locally. Many veterans reported that despite a desire to travel outside of Canada, they have held back because they do not want to have to return to relying on other medications (e.g., opioids) for symptom management. Unfortunately, traveling with medicinal cannabis internationally will remain a challenge for the foreseeable future and is not a problem that can be rectified without an international shift in perceptions around cannabis use.

Stigma around Cannabis Use

A frequently reported barrier experienced by veterans in this study was stigma around cannabis use. This echoes work by Gibson et al.Citation55 who conducted a qualitative study on perceptions of alcohol and cannabis use among male Canadian veterans with PTSD (N = 5) and observed that participants hesitated to use cannabis, even when medically prescribed, because they were concerned about how they may be perceived by their peers and society at large. As observed by Compton et al.Citation63 stereotypes and biases about cannabis users continue to persist despite a general increase in the acceptability of cannabis use within society. It is common for veterans to experience self-stigma around cannabis use,Citation35 owing in part to deeply ingrained institutional military regulations and values prohibiting cannabis use.Citation55 In a qualitative study on stigma around cannabis use among older veterans in the United States engaged in medicinal cannabis use (N = 32, 94% male, Mage = 71), Clary et al.Citation21 identified three themes: (1) negative stereotypes regarding people who use cannabis, (2) negative portrayals of people who use cannabis in the media, and (3) hesitation in disclosing medicinal cannabis use to friends, family, and physicians. One quote from a participant in the Clary et al.Citation21 study is illustrative: “Yeah, I know most people think oh yeah medical cannabis, just an excuse for people, to get you know, pot so they can get high.”(pCitation4) The fear of disclosing medicinal cannabis use could be isolating, particularly for veterans using it to manage symptoms associated with chronic pain or PTSD, with potential consequences to their health and well-being.Citation21 Even in the Canadian context where medicinal cannabis has been legal for more than a decade, social norms around medicinal use remain unfavorable for many populations.Citation42 Of note, there is less stigma around the use of cannabis oil as compared to smoking,Citation35 and media portrayals of cannabis users are becoming more positive,Citation21 signaling that stigma may become less of an issue over time.

Questions and Concerns about Cannabis Use

Another frequently reported barrier experienced by veterans in this study was a lack of scientific medical knowledge around cannabis use among medical practitioners and within the medical system generally. In a qualitative study on medicinal cannabis use among community-dwelling older Canadian adults (N = 12, age 65+), Baumbusch and Sloan YipCitation36 observed that older adults received little guidance from their family physician and relied on information from other sources, such as friends, cannabis store staff, and the media. Several reasons have been proposed for why many physicians are reluctant to prescribe cannabis and, even when they prescribe, offer little guidance to their patients. According to Ng et al.,Citation57 lingering stigma within health care, a lack of training and resources, and insufficient clinical evidence may all contribute to a physician’s hesitancy to prescribe cannabis. This is coupled with many physicians resenting that the government has made them the gatekeepers to what they consider to be an unproven drug.Citation44 A related barrier is the growing shortage of family physicians in Canada—which means reduced access to care for all Canadians, veterans included.Citation46

Limitations and Recommendations for Further Research

This was a qualitative investigation and cannot speak to the causal relationship between factors. As in any study reliant on participant self-report, the validity of the information collected in this study is limited by the accuracy of each veteran’s self-report. The small sample size (N = 12) and limited regional, ethnic, and racial diversity of the sample may reduce the generalizability of the findings to the wider veteran population. Unfortunately, limited sociodemographic information was collected for each participant. This was determined to be an acceptable trade-off for this study given the nature of the focus groups and the desire to offer participants confidentiality. We did not engage in member-checking of our thematic analysis, which limits its trustworthiness. Given the qualitative nature of the study, we were unable to determine the prevalence or relative importance of the various issues brought up; however, this study provides valuable information for future research in this area.

Future research should further explore cannabis use behaviors, reasons for cannabis use, and outcomes from cannabis use, as well as the relative impact of each of the identified facilitators and barriers to cannabis use among a larger and more diverse sample of Canadian veterans. Rigorous peer-reviewed research is needed to identify what dose, strain, form, and schedule of administration is best suited for which symptoms under which conditions. It is also important to determine the potential long-term effects of medicinal cannabis use, something that concerns many veterans who rely on medical cannabis for daily symptom management. Lastly, more research is needed to understand the roles that social, structural, and self-stigma play in veterans’ experiences around medicinal cannabis use, and to what degree legalization of the recreational market has impacted experiences of stigma.

Conclusion

The veterans included in this study experienced a range of health conditions and reported a history of using multiple medications to treat those conditions, often experiencing negative side effects. Being able to replace multiple medications with cannabis was reported to result in markedly beneficial outcomes for most participants, leading to fewer adverse effects. That said, a lack of guidance surrounding dosing remains a concern for veterans. Disruptions in supply, difficulty switching providers, restrictions on driving and travel, stigma, and a lack of scientific medical knowledge around cannabis presented ongoing challenges to veterans. The expansion of the VAC medical cannabis program coupled with the ease of receiving coverage has been accompanied by the growth of a private medical cannabis industry serving the needs of veterans. Most of the veterans in this study reported being happy with the VAC reimbursement program, as well as the service they have received from private clinics. Concern remains around the discrepancy between qualitative reports of beneficial outcomes from medicinal cannabis use and equivocal findings around the benefit-to-harm ratio in the wider literature. Currently, the VAC reimbursement program remains challenged by unclear indication for which veterans, with what condition(s), at what dose, and in what form medical cannabis is most beneficial. Future research is needed to help answer these questions to ensure that the reimbursement program remains viable and veterans receive safe and effective care.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author, JR. The data are not publicly available because they contain information that could compromise the privacy of research participants.

Disclosure Statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was approved by the Hamilton Integrated Research Ethics Board (HiREB Project No. 13619). This project is funded by the Government of Canada and the Chronic Pain Centre of Excellence (CPCoE) for Canadian veterans.

References

  • VanDenKerkhof EG, VanTil L, Thompson JM, Sweet J, Hopman WM, Carley ME, Sudom K. Pain in Canadian veterans: analysis of data from the survey on transition to civilian life. Pain Res Manage. 2015;20(2):89–21. doi:10.1155/2015/763768.
  • VAC Research Directorate. Chronic pain in Veterans. Ottawa (ON): Veterans Affairs Canada (VAC); 2018.
  • Foley HE, Knight JC, Ploughman M, Asghari S, Audas R. Association of chronic pain with comorbidities and health care utilization: a retrospective cohort study using health administrative data. Pain. 2021;162(11):2737–49. doi:10.1097/j.pain.0000000000002264.
  • Perera E, Thompson JM, Asmundson GJ, El-Gabalawy R, Afifi TO, Sareen J, Bolton S-L. Chronic pain: the Canadian Armed Forces members and Veterans mental health follow-up survey. J Mil Veteran Fam. 2021;7(S2):29–42. doi:10.3138/jmvfh-2021-0051.
  • Travaglini LE, Cosgrave J, Klingaman EA. Pain and sleep problems predict quality of life for veterans with serious mental illness. Psychiatr Rehabil J. 2019;42(3):229. doi:10.1037/prj0000358.
  • Berey BL, Aston ER, Kearns NT, McGeary JE, Borsari B, Metrik J. Prospective associations between sleep disturbances and cannabis use among Veterans: a behavioral economic approach. Addict Behav. 2022;134:107424. doi:10.1016/j.addbeh.2022.107424.
  • Afolalu EF, Ramlee F, Tang NKY. Effects of sleep changes on pain-related health outcomes in the general population: a systematic review of longitudinal studies with exploratory meta-analysis. Sleep Med Rev. 2018;39:82–97. doi:10.1016/j.smrv.2017.08.001.
  • Saconi B, Polomano RC, Compton PC, McPhillips MV, Kuna ST, Sawyer AM. The influence of sleep disturbances and sleep disorders on pain outcomes among veterans: a systematic scoping review. Sleep Med Rev. 2021;56:101411. doi:10.1016/j.smrv.2020.101411.
  • Qureshi AR, Makanjuola O, Neumark S, Garas A, Wang L, Busse JW. Research priorities among Canadian military Veterans living with chronic pain: a cross-sectional survey. Mil Med. 2022. doi:10.1093/milmed/usac309.
  • Ziemianski D, Ware MA. Canada’s marihuana for medical purposes regulations: a synopsis for health professionals. J Hosp Adm. 2015;4(5):79. doi:10.5430/jha.v4n5p79.
  • VAC Research Directorate. Cannabis for medical purposes. Ottawa (ON): Veterans Affairs Canada (VAC); 2022.
  • VAC. Cannabis for medical purposes - revised reimbursement policy. Ottawa (ON): Veterans Affairs Canada (VAC), ed; 2019.
  • Government of Canada. Cannabis Act. Ottawa (ON): Government of Canada; 2018
  • Turna J, MacKillop J. Cannabis use among military veterans: a great deal to gain or lose? Clin Psychol Rev. 2021;84:101958. doi:10.1016/j.cpr.2021.101958.
  • Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755–E96. doi:10.36076/ppj.20.5.E755.
  • Abrams DI. The therapeutic effects of Cannabis and cannabinoids: an update from the national academies of sciences, engineering and medicine report. Eur J Intern Med. 2018;49:7–11. doi:10.1016/j.ejim.2018.01.003.
  • Banerjee S, McCormack S. Medical cannabis for the treatment of chronic pain: a review of clinical effectiveness and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jul 24.
  • Wilkinson ST, van Schalkwyk GI, Davidson L, D’Souza DC. The formation of marijuana risk perception in a population of substance abusing patients. Psychiatr Q. 2016;87(1):177–87. doi:10.1007/s11126-015-9369-z.
  • Croulet J. Perceptions of cannabis use in combat Veterans: A cross-sectional case study [ Doctoral dissertation]. Northcentral University; 2018.
  • Clary K, Habbal M, Smith D, Fratila I. The green sheep: exploring the perceived risks and benefits of cannabis among young military members and Veterans. Cannabis. 2021;4(2):31–46. doi:10.26828/cannabis/2021.02.003.
  • Clary KL, Kang H, Quintero Silva L, Bobitt J. Weeding out the stigma: older Veterans in Illinois share their experiences using medical cannabis. J Psychoactive Drugs. 2022;1–8. doi:10.1080/02791072.2022.2082901.
  • Earleywine M, Bolles JR. Marijuana, expectancies, and post-traumatic stress symptoms: a preliminary investigation. J Psychoactive Drugs. 2014;46(3):171–77. doi:10.1080/02791072.2014.920118.
  • Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache. 2018;58:1139–86.
  • Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162–65. doi:10.1016/j.drugalcdep.2013.12.008.
  • Tull MT, Jakupcak M, Paulson A, Gratz KL. The role of emotional inexpressivity and experiential avoidance in the relationship between posttraumatic stress disorder symptom severity and aggressive behavior among men exposed to interpersonal violence. Anxiety Stress Coping. 2007;20(4):337–51. doi:10.1080/10615800701379249.
  • VAC Research Directorate. Measuring Veteran well-being. Ottawa (ON): Veterans Affairs Canada (VAC), ed; 2019.
  • Guest G, Namey E, McKenna K. How many focus groups are enough? Building an evidence base for nonprobability sample sizes. Field Methods. 2017;29(1):3–22. doi:10.1177/1525822X16639015.
  • Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82. doi:10.1177/1525822X05279903.
  • Government of Canada. Statistics of women in the Canadian armed forces. Ottawa (ON): Government of Canada; 2022.
  • NVivo. Ver. 14.0 [software]. Denver (CO): Lumivero; 2023 Mar 14.
  • Cotter A. Sexual misconduct in the Canadian armed forces regular force. Ottawa (ON): Statistics Canada; 2018.
  • DeCuir-Gunby JT, Marshall PL, McCulloch AW. Developing and using a codebook for the analysis of interview data: an example from a professional development research project. Field Methods. 2011;23(2):136–55. doi:10.1177/1525822X10388468.
  • Glaser BG. The constant comparative method of qualitative analysis. Soc Probl. 1965;12(4):436–45. doi:10.2307/798843.
  • Glaser BG, Strauss AL, Strutzel E. The discovery of grounded theory; strategies for qualitative research. Nurs Res. 1968;17(4):364. doi:10.1097/00006199-196807000-00014.
  • VAC. Demographics. Ottawa (ON): Veterans Affairs Canada (VAC), ed; 2021.
  • Krediet E, Janssen DG, Heerdink ER, Egberts TC, Vermetten E. Experiences with medical cannabis in the treatment of veterans with PTSD: results from a focus group discussion. Eur Neuropsychopharmacol. 2020;36:244–54. doi:10.1016/j.euroneuro.2020.04.009.
  • Baumbusch J, Sloan Yip I. Exploring new use of cannabis among older adults. Clin Gerontol. 2021;44(1):25–31. doi:10.1080/07317115.2020.1746720.
  • Benedetti F, Carlino E, Pollo A. How placebos change the patient’s brain. Neuropsychopharmacology. 2011;36(1):339–54. doi:10.1038/npp.2010.81.
  • Benedetti F, Amanzio M, Rosato R, Blanchard C. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med. 2011;17(10):1228–30. doi:10.1038/nm.2435.
  • Casarett D. The achilles heel of medical cannabis research—inadequate blinding of placebo-controlled trials. JAMA Intern Med. 2018;178(1):9–10. doi:10.1001/jamainternmed.2017.5308.
  • Dondanville KA, Blankenship AE, Molino A, Resick PA, Wachen JS, Mintz J, Yarvis JS, Litz BT, Borah EV, Roache JD. Qualitative examination of cognitive change during PTSD treatment for active duty service members. Behav Res Ther. 2016;79:1–6. doi:10.1016/j.brat.2016.01.003.
  • Haney M, Evins AE. Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology. 2016;41(2):393–401. doi:10.1038/npp.2015.251.
  • Leos‐Toro C, Shiplo S, Hammond D. Perceived support for medical cannabis use among approved medical cannabis users in Canada. Drug Alcohol Rev. 2018;37(5):627–36. doi:10.1111/dar.12823.
  • Ng JY, Gilotra K, Usman S, Chang Y, Busse JW. Attitudes toward medical cannabis among family physicians practising in Ontario, Canada: a qualitative research study. Can Med Assoc J. 2021;9:E342–E8.
  • Lough S. Private cannabis clinics offer clients access. Can Med Assoc. 2015;187(12):865–66. doi:10.1503/cmaj.109-5119.
  • Prosk E, Arboleda MF, Rapin L, El Hage C, Dworkind M. The model of care at a leading medical cannabis clinic in Canada. Complement Ther Med. 2021;60:102740. doi:10.1016/j.ctim.2021.102740.
  • The College of Family Physicians of Canada. Family doctor shortage in Canada. 2022 [accessed 2022 Nov 14]. https://www.cfpc.ca/en/news-and-events/news-events/news-events/news-releases/2022/family-doctor-shortage-in-canada.
  • Kahan M, Srivastava A, Clarke S. Cannabis industry and medical cannabis clinics need regulation. Can Fam Physician. 2019;65:864–68.
  • Hammond D. Communicating THC levels and ‘dose’to consumers: implications for product labelling and packaging of cannabis products in regulated markets. Int J Drug Policy. 2021;91:102509. doi:10.1016/j.drugpo.2019.07.004.
  • Nyland CR, Moyer DC. Regulating for safety: cannabidiol dose in food: a review. J Food Prot. 2022;85(9):1355–69. doi:10.4315/JFP-21-374.
  • MacCallum CA, Lo LA, Boivin M. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Intern Med. 2021;89:10–18. doi:10.1016/j.ejim.2021.05.002.
  • Fischer B, Russell C, Sabioni P, Van Den Brink W, Le Foll B, Hall W, Rehm J, Room R. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. Am J Public Health. 2017;107(8):e1–e12. doi:10.2105/AJPH.2017.303818.
  • Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, Clarke H, Cooper ZD, Cyr C, Daeninck P, Deshpande A. Consensus‐based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract. 2021;75(8):e13871. doi:10.1111/ijcp.13871.
  • Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, Cyr C, Eisenberg E, de Oliveira Silva RF, Frohlich E. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3(1):1–12. doi:10.1186/s42238-021-00073-1.
  • Busse JW, Vankrunkelsven P, Zeng L, Heen AF, Merglen A, Campbell F, Granan L-P, Aertgeerts B, Buchbinder R, Coen M. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ. 2021;374:n2040. doi:10.1136/bmj.n2040.
  • Gibson M, Williamson L, Henwood G, Chalmers D, Dell CA. Perceptions and use of alcohol and medical Cannabis among Canadian military veterans living with PTSD. J Veterans Stud. 2021;7(1):59. doi:10.21061/jvs.v7i1.200.
  • Shanahan M, Cyrenne P. Cannabis policies in Canada: how will we know which is best? Int J Drug Policy. 2021;91:102556. doi:10.1016/j.drugpo.2019.09.004.
  • Ng JY, Homayouni P, Usman S, Gomes Z. The medical cannabis regulatory framework in Canada: a narrative review. Eur J Integr Med. 2022;50:102104. doi:10.1016/j.eujim.2022.102104.
  • Wickens CM, Stoduto G, Ilie G, Di Ciano P, McDonald AJ, Mistry A, Alawi A, Sharma S, Hamilton H, Nigatu YT. Driving under the influence of cannabis among recreational and medical cannabis users: a population study. J Transp Health. 2022;26:101402. doi:10.1016/j.jth.2022.101402.
  • Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. Bmj. 2012;344(feb09 2):e536. doi:10.1136/bmj.e536.
  • Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction. 2016;111(8):1348–59. doi:10.1111/add.13347.
  • M-C L, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G. Marijuana use and motor vehicle crashes. Epidemiol Rev. 2012;34(1):65–72. doi:10.1093/epirev/mxr017.
  • Brands B, Di Ciano P, Mann RE. Cannabis, impaired driving, and road safety: an overview of key questions and issues. Front Psychiatry. 2021;12:641549. doi:10.3389/fpsyt.2021.641549.
  • Compton WM, Han B, Jones CM, Blanco C, Hughes A. Marijuana use and use disorders in adults in the USA, 2002–14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016;3(10):954–64. doi:10.1016/S2215-0366(16)30208-5.

Appendix

Focus group guide.